来自阿尔茨海默氏症的循环外体抑制血管内皮-卡德林表达,并诱导受体大脑微血管内皮细胞中的屏障功能障碍
Jiani Bei1, Ernesto G Miranda-Morales2, Qini Gan3
1Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Journal of Alzheimer's disease : JAD
|September 4, 2023
概括
阿尔茨海默病 (AD) 患者的外体会损害大脑内皮细胞,削弱血脑屏障 (BBB). 这种外体诱导的功能障碍与减少的血管内皮卡德林有关,并取决于外体的RNA含量,影响AD中的BBB完整性.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 血脑屏障 (BBB) 的破坏是阿尔茨海默病 (AD) 进展的关键因素.
- 在大脑微血管内皮细胞 (BMEC) 中,附着结合蛋白功能障碍有助于BBB损伤.
- 来自老化细胞的外体在与AD相关的BBB功能障碍中的特定作用尚不清楚.
研究的目的:
- 研究AD患者循环外体对大脑内皮细胞功能的影响.
- 阐明AD外基因组影响血脑屏障完整性的机制.
主要方法:
- 从AD患者和健康对照者的血清中分离出外体.
- 大脑微血管内皮细胞 (BMEC) 用AD外体进行治疗,以评估屏障功能和VE-cadherin表达.
- 使用3DBBBB模型和人类大脑组织样本来验证结果.
主要成果:
- 来自AD患者的外体细胞减少了血管内皮质 (VE) - 阴素表达和受体BMEC的障碍功能受损.
- 在3D微血管模型中,AD外体损坏了VE-cadherin完整性,表明BBB.受损.
- 与对照人群相比,在AD患者的大脑中观察到微血管VE-cadherin表达的减少.
结论:
- 来自AD患者的循环外体在破坏BMEC中的附着结处中发挥着重要作用.
- 在AD外体的RNA含量对于它们对BBB完整性的有害影响至关重要.
- 这些发现提供了对阿尔茨海默症病原和BBB功能障碍的潜在治疗点的见解.
相关概念视频
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517


